File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The Hurdles From Bench to Bedside in the Realization and Implementation of a Universal Influenza Vaccine

TitleThe Hurdles From Bench to Bedside in the Realization and Implementation of a Universal Influenza Vaccine
Authors
KeywordsInfluenza virus
Universal vaccine
T cell
Hemagglutinin-stalk
Clinical trials
Issue Date2018
PublisherFrontiers Research Foundation. The Journal's web site is located at http://www.frontiersin.org/immunology
Citation
Frontiers in Immunology, 2018, v. 9, article no. 1479 How to Cite?
AbstractInfluenza viruses circulate worldwide causing annual epidemics that have a substantial impact on public health. This is despite vaccines being in use for over 70 years and currently being administered to around 500 million people each year. Improvements in vaccine design are needed to increase the strength, breadth, and duration of immunity against diverse strains that circulate during regular epidemics, occasional pandemics, and from animal reservoirs. Universal vaccine strategies that target more conserved regions of the virus, such as the hemagglutinin (HA)-stalk, or recruit other cellular responses, such as T cells and NK cells, have the potential to provide broader immunity. Many pre-pandemic vaccines in clinical development do not utilize new vaccine platforms but use “tried and true” recombinant HA protein or inactivated virus strategies despite substantial leaps in fundamental research on universal vaccines. Significant hurdles exist for universal vaccine development from bench to bedside, so that promising preclinical data is not yet translating to human clinical trials. Few studies have assessed immune correlates derived from asymptomatic influenza virus infections, due to the scale of a study required to identity these cases. The realization and implementation of a universal influenza vaccine requires identification and standardization of set points of protective immune correlates, and consideration of dosage schedule to maximize vaccine uptake.
Persistent Identifierhttp://hdl.handle.net/10722/261232
ISSN
2019 Impact Factor: 5.085
2015 SCImago Journal Rankings: 2.810
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorValkenburg, SA-
dc.contributor.authorLeung, NHL-
dc.contributor.authorBull, MB-
dc.contributor.authorYan, L-
dc.contributor.authorLi, APY-
dc.contributor.authorPoon, LLM-
dc.contributor.authorCowling, BJ-
dc.date.accessioned2018-09-14T08:54:43Z-
dc.date.available2018-09-14T08:54:43Z-
dc.date.issued2018-
dc.identifier.citationFrontiers in Immunology, 2018, v. 9, article no. 1479-
dc.identifier.issn1664-3224-
dc.identifier.urihttp://hdl.handle.net/10722/261232-
dc.description.abstractInfluenza viruses circulate worldwide causing annual epidemics that have a substantial impact on public health. This is despite vaccines being in use for over 70 years and currently being administered to around 500 million people each year. Improvements in vaccine design are needed to increase the strength, breadth, and duration of immunity against diverse strains that circulate during regular epidemics, occasional pandemics, and from animal reservoirs. Universal vaccine strategies that target more conserved regions of the virus, such as the hemagglutinin (HA)-stalk, or recruit other cellular responses, such as T cells and NK cells, have the potential to provide broader immunity. Many pre-pandemic vaccines in clinical development do not utilize new vaccine platforms but use “tried and true” recombinant HA protein or inactivated virus strategies despite substantial leaps in fundamental research on universal vaccines. Significant hurdles exist for universal vaccine development from bench to bedside, so that promising preclinical data is not yet translating to human clinical trials. Few studies have assessed immune correlates derived from asymptomatic influenza virus infections, due to the scale of a study required to identity these cases. The realization and implementation of a universal influenza vaccine requires identification and standardization of set points of protective immune correlates, and consideration of dosage schedule to maximize vaccine uptake.-
dc.languageeng-
dc.publisherFrontiers Research Foundation. The Journal's web site is located at http://www.frontiersin.org/immunology-
dc.relation.ispartofFrontiers in Immunology-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectInfluenza virus-
dc.subjectUniversal vaccine-
dc.subjectT cell-
dc.subjectHemagglutinin-stalk-
dc.subjectClinical trials-
dc.titleThe Hurdles From Bench to Bedside in the Realization and Implementation of a Universal Influenza Vaccine-
dc.typeArticle-
dc.identifier.emailValkenburg, SA: sophiev@hku.hk-
dc.identifier.emailLeung, NHL: nanleung@connect.hku.hk-
dc.identifier.emailYan, L: ylmeng@hku.hk-
dc.identifier.emailPoon, LLM: llmpoon@hkucc.hku.hk-
dc.identifier.emailCowling, BJ: bcowling@hku.hk-
dc.identifier.authorityValkenburg, SA=rp02141-
dc.identifier.authorityLeung, NHL=rp02637-
dc.identifier.authorityPoon, LLM=rp00484-
dc.identifier.authorityCowling, BJ=rp01326-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.3389/fimmu.2018.01479-
dc.identifier.pmid30013557-
dc.identifier.pmcidPMC6036122-
dc.identifier.scopuseid_2-s2.0-85049412598-
dc.identifier.hkuros291113-
dc.identifier.hkuros287950-
dc.identifier.volume9-
dc.identifier.spagearticle no. 1479-
dc.identifier.epagearticle no. 1479-
dc.identifier.isiWOS:000436992400001-
dc.publisher.placeSwitzerland-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats